2Belongia EA,Costa J,Gareen IF,et al.NIH consensus developmentstatement on management of hepatitis B[J]. NIH Consens State Sci Stmemenls _ 2009 _ 25 ( 2 ): l -29.
3Delaney WE,Ray AS,Yang H,et aHntracellular metabolism and in vitro activity of tenofovir against hepatitis B virus[J]. Antimicrob Agents Chemother, 2006,50 (7) :2471-2477.
4Lamorde M, Byakika-Kibwika P,Tamale WS,et al.Effect of food on the steady-state pharmacokinetics of tenofovir and emtricitabine plus efavirenz in ugandan aduhs[J]. AIDS Res Treat,2012,2012:105980.
5Xiong X, Yang H, Westland CE,et al.In vitro evaluation of hep- atitis B virus polymerase mutations associated with famciclovin re- sistence[J].Hepatol, 2000,31 ( 1 ):219-224.
6Yao GB, Zhu M, Cui ZY, et al. A 7-year study of lamivudine therapy for hepatitis B virus e antigen-positive chronic hepatitis B patients in China[J]. J Dig Dis, 2009,10(2):131-137.
7Tenney DJ, Rose RE, Baldick C J, et al. Long-term monitoring shows hepatitis B virus resistangce to entecavir in nucleoside- naive patients is rare through 5 years of therapy [J]. Hepatology, 2009, 49(5): 1503-1514.
8Fung S, Kwan P, Fabri M, et al. Randomized comparison of tenofovir disoproxil fumarate vs emtricitabine and tenofovir diso- proxil fumarate in patients with lamivudine-resistant chronic hep- atitis B[J]. Gastroenterology, 2014, 46(4): 980-988.
9van Bommel F, de Man RA, Wedemeyer H, et al. Long-term ef- ficacy of tenofovir monotherapy for hepatitis B virus-monoinfeeted patients after failure of nueleoside/nucleotide analogues[J]. Hepa- tology, 2010, 51 (1): 73-80.
10Baran B, Soyer OM, Ormeci AC,et al.Efficacy of tenofovir in pa- tients with Lamivudine failure is not different from that in nucleo- side/nucleotide anaIogue-nafve patients with chronic hepatitis B[J]. Antimicrob Agents Chemother, 2013,57 ( 4 ) : 1790-1796.
